Based on the suppression in PGE2 production and IL-8 secretion, further investigation of the MEK/ERK signaling pathway may inform future therapeutic strategies to treat inflammatory diseases such as SLE and DM. This evidence concerns the gene CXCL8 and dermatomyositis.